We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recombinant Human Soluble Thrombomodulin in Patients With Sepsis-Associated Coagulopathy: Another Negative Sepsis Trial?
- Authors
van der Poll, Tom
- Abstract
The article discusses research on the results of the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin (SCARLET) phase 3 trial that examined the effect of soluble human recombinant thrombomudulin, an anticoagulant, on patients with sepsis-associated coagulopathy and cardiovascular and respiratory failure. Topics discussed include the anticoagulant, anti-inflammatory and cytoprotective effects of thrombomodulin in patients with sepsis and no effect in reduction mortality of patients.
- Subjects
THROMBOMODULIN; LECTINS; THROMBIN receptors; SEPSIS; CIRCULATING anticoagulants; DISSEMINATED intravascular coagulation; BACTERIAL cell walls; CELL receptors
- Publication
JAMA: Journal of the American Medical Association, 2019, Vol 321, Issue 20, p1978
- ISSN
0098-7484
- Publication type
editorial
- DOI
10.1001/jama.2019.5792